POSC166 Cost-Effectiveness of Emicizumab Prophylaxis Therapy Versus Recombinant Activated FVII On-Demand Therapy for Hemophilia A with Inhibitors in China
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.568
https://www.valueinhealthjournal.com/article/S1098-3015(21)02363-9/fulltext
Title :
POSC166 Cost-Effectiveness of Emicizumab Prophylaxis Therapy Versus Recombinant Activated FVII On-Demand Therapy for Hemophilia A with Inhibitors in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02363-9&doi=10.1016/j.jval.2021.11.568
First page :
Section Title :
Open access? :
No
Section Order :
10104